Innosphere starts paediatric clinical trial for Novostim ADHD device [Yahoo! Finance]
Akili, Inc. (AKLI)
Company Research
Source: Yahoo! Finance
The randomised, sham-controlled trial will evaluate the Novostim 2 device in children with ADHD aged 7-12 years. The data from the study will be used to seek clearance from the US Food and Drug Administration (FDA). The Novostim treatment will be administered over 20 minutes, where patient attention will be maintained using a “digital engagement game”. The study will last for two months, and the participants will receive treatment for ten days for two weeks. Novostim 2 is a transcranial random noise stimulation (tRNS) device. "Novostim 2 uses a non-invasive technique where a weak signal is applied to the brain, subtly enhancing brain activity,” said Dr Cesar A Soutullo, director of the ADHD Outpatient Program at McGovern Medical School, UTHealth Houston. “It is like a buzzing sensation to the brain that may activate some regions important for attention by making your brain's natural activities change or become more efficient." GlobalData has identified digital therapeutics as
Show less
Read more
Impact Snapshot
Event Time:
AKLI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AKLI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AKLI alerts
High impacting Akili, Inc. news events
Weekly update
A roundup of the hottest topics
AKLI
News
- Akili Reports First Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]Yahoo! Finance
- Akili Reports First Quarter 2024 Financial Results and Provides Business UpdateBusiness Wire
- Global Digital Biomarkers Market Trends and Forecasts to 2035: Leading Players are AliveCor, BACtrack, Biogen, BioSensics, Empatica, Eyenuk, Feel Therapeutics, Icometrix, and Quibim [Yahoo! Finance]Yahoo! Finance
- Akili Announces Amended Agreement with Shionogi, Shift in Corporate Strategy and Release Date for First Quarter 2024 Financial Results [Yahoo! Finance]Yahoo! Finance
- Akili Announces Amended Agreement with Shionogi, Shift in Corporate Strategy and Release Date for First Quarter 2024 Financial ResultsBusiness Wire
AKLI
Sec Filings
- 5/14/24 - Form 10-Q
- 5/14/24 - Form 8-K
- 5/6/24 - Form 4
- AKLI's page on the SEC website